Gilead Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Gilead Sciences (GILD).

Price Target Range — 9 Quarters

Analyst Consensus — 23 Analysts

19Buy

4Hold

Consensus RatingBuy# Analysts23Avg. Consensus PT$138Upside to Avg. PT-8.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$123→$126
Oct 8, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$155
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$150→$158
Oct 7, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$160→$170
Oct 7, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$165→$163
Sep 10, 2026	HSBC	Morten Herholdt	PT Raise	Buy	$155→$175
Aug 5, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$120→$123
Aug 5, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$155
Aug 5, 2026	Needham	Joseph Stringer	Maintained	Buy	$170
Jul 29, 2026	Barclays	Emily Field	PT Cut	Equal-Weight	$155→$145
Jul 27, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$166→$165
Jul 21, 2026	Leerink Partners	Daina Graybosch	Downgrade	Outperform→Market Perform	$146→$127
Jul 8, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$168→$166
Jul 7, 2026	RBC Capital	Brian Abrahams	PT Cut	Sector Perform	$122→$120
Jul 7, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$157→$156
Jul 6, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$155
Jul 6, 2026	HSBC	Morten Herholdt	Upgrade	Hold→Buy	$133→$155
Jun 16, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$155
May 20, 2026	Maxim Group	Michael Okunewitch	Upgrade	Hold→Buy	$165
May 8, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$155→$157

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $123 to $126.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158

Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $150 to $158.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170

JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $160 to $170.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $165 to $163.

Benzinga Newsdesk

PRO
HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175

HSBC analyst Morten Herholdt maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $155 to $175.

Benzinga Newsdesk

Gilead Sciences Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Gilead Sciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126

PRO
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163

PRO
HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175

People Also Watch

People Also Watch

Gilead Sciences Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Gilead Sciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126

PROCantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

PROTruist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158

PROJP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170

PROMorgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163

PROHSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126

PRO
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163

PRO
HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175